PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation

BACKGROUND: Since ovarian cancer is associated with high frequency of p53 mutation, the availability of p53 reactivation and induction of massive apoptosis (PRIMA-1) offers a possible new therapeutic strategy for overcoming this devastating disease. Although Akt activation is believed to be a determ...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Kobayashi, Noriko, Abedini, Mohammadreza, Sakuragi, Noriaki, Tsang, Benjamin K
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2013
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3636020/
https://ncbi.nlm.nih.gov/pubmed/23351152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1757-2215-6-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky